Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California. Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006.

EpiCept has made leukemia remission its entire mission. Its lead cancer drug candidate, Ceplene, is designed for use in adult patients who have had a complete remission from acute myeloid leukemia, but who are still at risk for relapse. It has been approved for use, along with interleukin-2, as a remission maintenance therapy in the EU, and it is awaiting approval in the US. The company's pipeline includes other cancer candidates, as well as topical analgesics for both acute and chronic pain. However, EpiCept has put all drug-discovery work on the back burner to focus on bringing Ceplene to market.

Pharsight wants to shorten the path to market for tomorrow's pharmaceutical breakthroughs. The company's software and consulting services aim to take some of the guesswork out of the drug development process for pharmaceutical and biotech firms, helping them choose the most promising drug candidates, to design effective clinical trials, and to keep up with regulatory reporting. Pharsight's WinNonlin and WinNonMix applications, for instance, analyze research and clinical data to help companies develop appropriate dosing regimens for clinical trials. And its consulting services help them make key strategy decisions about the future of development programs. Pharsight was acquired by Tripos in 2008.

AVI BioPharma, Inc. was founded in 1980 and is based in Corvallis, Oregon. AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The company's products under various development stages comprise AVI-4658, a Phase I human clinical trial product to restore, prevent, or slow deterioration of muscle function; AVI-5038, a preclinical stage product to skip exon 50 and restore a range of associated mutations; AVI-5126, a Phase II clinical trial product for the treatment of cardiovascular restenosis; and AVI-6002 and AVI6003, which are in Phase I clinical trials to treat diseases caused by Dengue, Ebola, Marburg, and Junín viruses. It has strategic alliances with Chiron Corporation; Cook Group Incorporated; Ercole Biotech, Inc.; Eleos Inc.; Charley's Fund, Inc.; and the United States Department of Defense.

Shionogi Pharma, Inc. company was founded in 1992 and is headquartered in Atlanta, Georgia. Sciele Pharma Inc. operates as a subsidiary of Shionogi & Co. Ltd. Sciele Pharma Inc., a pharmaceutical company, engages in acquiring, developing, marketing, and selling prescription products for patients primarily in the United States. It offers oral suspensions, tablets, and capsules, as well as products prescribed by the primary care physicians. The company provides cardiovascular and diabetes products that treat patients with high cholesterol, hypertension, high triglycerides, unstable angina, and Type 2 diabetes; pediatrics products, which treat allergies, asthma, cough and cold, and attention deficit and hyperactivity disorders; and products for the health and well-being of women, as well as for mothers and their babies. It develops glycopyrrolate oral solution, a treatment for chronic, moderate-to-severe drooling in pediatric patients.

Medarex is building the ultimate monoclonal antibody. Its UltiMAb technology utilizes transgenic mice whose antibody gene expression is suppressed to create fully human monoclonal antibodies (single-source proteins). Medarex has more than 40 antibodies for cancer, rheumatoid arthritis, and other autoimmune, inflammatory, and infectious diseases in clinical trials or pre-trial stages. The company has partnerships with numerous pharma and biotech firms including Genmab, which has licensed antibody therapies for leukemia, arthritis, and other conditions. Other development partners include Pfizer, Amgen, Eli Lilly, and Kirin. Another major collaborator, Bristol-Myers Squibb, acquired Medarex for $2.4 billion in 2009.

XELR8 Holdings, Inc. was founded in 2000 and is based in Denver, Colorado. XELR8 Holdings, Inc. is engaged in developing, selling, marketing and distributing nutritional supplement products through a direct sales or network marketing system in which independent distributors sells the products, as well as purchase them for their own personal use. The Company also sell the products directly to the professional and Olympic athletes, and to professional sports teams. During the year ended December 31, 2008, the Company discontinued the XELR8 Snack. The products of the Company include Bazi, XELR8 EAT, XELR8 DRINK, XELR8 HYDRATE, XELR8 BUILD, and vitamins and minerals, including XELR8 SUPPORT.

Eurand N.V. company was formerly known as Eurand B.V. Eurand N.V. was incorporated in 1984 and is based in Amsterdam, the Netherlands. Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. The company develops these products based on its proprietary customized release technologies used to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; Tastemasking/ODTs technologies to increase patient compliance through more convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technologies to improve drug absorption; and drug conjugation technologies to extend drug half-life and to target specific organs or other biological targets, such as tumors. Its technologies are used for applications in drug products used for various therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition, and respiratory.Eurand company offers EUR-1037, as an over-the-counter sleep-aid; EUR-1025, an oral formulation of ondansetron, an anti-emetic prescribed to prevent nausea and vomiting; and EUR-1073, an enteric coated, controlled release formulation of beclomethasone diproprionate for the treatment of inflammatory bowel disease. It products also include Zentase, also known as EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency, which has completed Phase III clinical trials; Amrix, a sustained release formulation of cyclobenzaprine hydrochloride, used as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions; and products and services to the cystic fibrosis community.

Orbus Pharma offers pharmaceutical research, manufacturing, packaging, and warehousing services on a contract basis for other drug companies. Orbus Pharma specializes in oral suspension and generic pharmaceutical products. The company serves the North American, European, and other international markets. It develops formulations of existing drugs using proprietary delivery systems and then provides out-licensing and contract manufacturing services for the products. Orbus has agreed to allow China-based pharmaceutical firm Nanjing Sanhome Pharmaceutical Co. to acquire a majority of its shares.

Ferndale Laboratories makes prescription and over the counter medications, with a primary focus on skin care maladies, including acne, dry skin, eczema, psoriasis, and inflammation. The company also makes topical pain relief creams, surgical adhesives and adhesive removers, and decongestants. Ferndale Laboratories markets its products to physicians and consumers. Ferndale company originally began selling vitamins, tonics, elixirs, and surgical instruments. It was founded in Detroit in 1897 as J. F. Hartz Company, the name it operated under until the mid-1950s when it changed its name to Ferndale Laboratories.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.